Related Experiment Video
Updated: Jan 15, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Persisting or Worsening Impulse Control Disorders in Parkinson's Disease Following a Switch to Subcutaneous
Maeve Bradley1,2, Eoghan Donlon1,2, Amy Gallagher1,2
1Dublin Neurological Institute at the Mater Misercordiae University Hospital, Dublin, Ireland.
Background:
Impulse control disorders (ICDs) are most often associated with dopamine agonists and pulsatile dopamine replacement therapy such as oral levodopa and subcutaneous apomorphine. Intestinal levodopa-carbidopa gel may improve ICDs through rationalization of dopaminergic agents and/or a reduction of pulsatile dopaminergic stimulation, however the impact of subcutaneous foslevodopa/foscarbidopa (CSFLI) has not been reported to date.
Cases:
We describe five men aged 50-68 with advanced Parkinson's disease (PD) and pre-existing ICDs who were switched to CSFLI. Four of them were transitioned directly from subcutaneous apomorphine infusions with the hope of improving ICD symptoms. All experienced worsening or persistent ICD symptoms, predominantly hypersexuality, after switching to CSFLI with a mean time to peak ICD symptoms of 4.5 weeks (range 2-6).
Conclusions:
CSFLI may exacerbate ICDs in susceptible individuals. Pre-treatment screening and close monitoring are recommended.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Desensitization and Tachyphylaxis

